Why Peptide Sciences Stopped Selling Tirzepatide (and Compliant Options)

Why did Peptide Sciences stop selling tirzepatide?

It was not a safety scandal, despite how it looked: Peptide Sciences pulled tirzepatide once the legal cover vanished, after the FDA declared the shortage resolved in December 2024 and closed the window for moving it as a research compound. The company then shut entirely in March 2026. For a tirzepatide-class option done right, my first pick is FormBlends, which requires a physician evaluation and a written script before shipping.

People kept asking me where their tirzepatide went, and the answer runs through a regulatory calendar rather than a business decision made in isolation. A drug shortage triggers temporary compounding allowances. Once the FDA calls that shortage over, the allowance closes, and a vendor selling a copy of a patented molecule under a research label is suddenly exposed. Tirzepatide came off the shortage list in late December 2024. Semaglutide followed on February 21, 2025. After those two dates, the grey market that had treated both as freely sellable research chemicals started looking at warning letters and lawsuits, and Peptide Sciences read the room and left.

The job here is to explain the closure honestly and then rank the realistic places a former buyer can actually go, scored on things anyone can verify.

How I sorted these options

I built a short checklist of questions a careful buyer can put to any peptide or GLP-1 source, then ordered the field by how many each one answers straight. For an audience leaving a vendor that just vanished mid-purchase, I lean hardest on whether a real clinician signs off and whether the operation can keep running inside the 2026 rules.

• Does a licensed prescriber clear you first? A clinician who reviews your case before a vial ships is the line between supervised care and a chemical bought on faith.
• Is a named 503A pharmacy doing the compounding? Sterile injectables belong to a specific FDA-registered pharmacy working under USP-797 and cGMP, not a warehouse.
• Will it survive 2026 enforcement? Operating inside the supervised framework, or sitting in the research-use-only zone now drawing FDA letters and brand lawsuits.
• Is it straight about FDA status? Compounded products are not FDA-approved, and admitting that beats implying otherwise.
• Can one account carry the range you need? A single clinical relationship that covers your compounds beats stitching together several vendors.

One source below sells strictly for laboratory use, judged here on what it actually is. A research-use-only seller is a separate product class, not a fraud by default, but it carries no prescriber, no pharmacy license, and no one who answers for a human outcome.

Two regulatory facts shape the tirzepatide story specifically, and both get garbled online. The shortage resolutions of December 2024 and February 2025 are what closed the compounding window for the GLP-1 copies, which is the direct reason a research vendor could no longer sell tirzepatide safely. Separately, the FDA moved several peptide bulk substances off the 503A Category 2 list on April 15, 2026, a step tied to nominations that were withdrawn rather than any safety reversal, and its Pharmacy Compounding Advisory Committee set hearing days for July 23 and 24, 2026 under docket FDA-2025-N-6895 to weigh seven peptides including BPC-157, TB-500, and MOTS-c. Those peptides are under review. They are not banned, and any page using that word is wrong.

The ranking: 5 compliant and not-so-compliant options, best to least

1. FormBlends: 9.2/10

FormBlends sits at the top because it answers the one question Peptide Sciences could not: who is accountable. A licensed physician reviews each patient and writes the prescription before fulfillment starts, which puts a named, answerable clinician at the front of the process rather than a checkout button. The order then goes to an FDA-registered 503A pharmacy that compounds it under USP-797 and cGMP for one specific patient, and that kind of compounding carries HPLC, mass-spec, and endotoxin testing as routine process.

For a tirzepatide refugee the fit is about coverage and continuity. A single FormBlends account reaches a wide peptide catalog across 47 states, with per-vial cash prices posted openly, cold-chain delivery at no charge, a care team available at any hour, and a reconstitution calculator included, so the scattered vendor accounts a grey-market buyer used to keep collapse into one supervised file. FormBlends also says plainly that compounded products are not FDA-approved, which is the honesty this market has lacked. It does not lead on a public certification number, and you should not pick it expecting one. Its claim to the top spot is the supervised, prescription-required, pharmacy-compounded model and the breadth of the catalog. An independent 2026 roundup, Where to Buy Peptides in 2026: 10 Options Compared, reached the same read from the outside.

2. HealthRX.com: 8.9/10

HealthRX.com runs a close second, and its turnaround is the standout. A US board-certified physician clears each patient in roughly a day, which is a fast supervised review compared with most of the category, and the order is dispensed by Manifest Pharmacy in Greer, South Carolina, a 503A pharmacy under USP-797 that HealthRX.com names on the record. It also holds a LegitScript certification, cert 50087439, that a buyer can confirm in the public registry inside a minute, the kind of outside check the old vendor never allowed. Pricing is published and shipping reaches all 50 states overnight. It lands just behind the leader on one point, catalog depth: the HealthRX.com peptide menu is narrower, so a buyer who wants the widest single-account range will find more at FormBlends.

3. Henry Meds (Adonis Health Inc.): 7.4/10

Henry Meds is a mainstream supervised route a lot of former GLP-1 buyers recognize. State-licensed providers, MDs, DOs, NPs, and PAs, review an intake and run a video or phone consult where state law requires it before issuing a prescription, and the medication is filled through US-licensed 503A compounding pharmacies. That clinician step is the part the grey market skipped. It places below the two leaders for documentation reasons rather than care quality. Henry Meds does not publicly name its pharmacy partners, one identified partner, Hallandale Pharmacy, received an FDA Form 483 in June 2025 over sterility findings, and the tirzepatide question hangs over it too: with tirzepatide off the shortage list, the legal room to compound it narrowed, the same squeeze that pushed Peptide Sciences out. It is cash-pay only, with no insurance billing.

4. Ro (Ro Body): 6.8/10

Ro is the most brand-forward option here and the one I would point a buyer to who wants the FDA-approved drug rather than a compounded copy. Licensed doctors and nurse practitioners run a telemedicine assessment and prescribe, and fulfillment moves through Ro’s own Roman Health Pharmacy plus a partner network. Through 2025 and into 2026 Ro leaned hard into approved branded GLP-1s, adding a Novo Nordisk arrangement for the Wegovy pill in January 2026, with compounded semaglutide kept only as a fallback in the states that still allow it. For a former tirzepatide buyer that pivot is the honest answer to the shortage resolutions: the compliant path now is usually the branded molecule. It ranks here, not higher, because it is not built around a named 503A peptide-compounding relationship the way the leaders are, and its compounded options are deliberately limited.

5. Precision Peptide Co: 4.7/10

Precision Peptide Co is where the list crosses into research-use-only ground, and it is the closest like-for-like to what Peptide Sciences shipped. It is a direct-to-consumer vendor selling lyophilized compounds, including research-grade semaglutide, tirzepatide, retatrutide, and BPC-157, every item labeled for research use only and explicitly not for human consumption. I put it at the bottom rather than off the list because it is still operating as of June 2026, it does not appear in any FDA enforcement announcement I could find, and it markets third-party testing as its quality angle. The hard limits are the same ones that defined the old model: no prescriber, no 503A or 503B license, and no one accountable if a person injects what is sold for a lab bench. Judged as a chemical supplier it is credible. Judged as a replacement for supervised care it is not, because it is not supervised care.

At a glance

Source	Oversight	503A	Legal	Catalog	Score
FormBlends	Yes	Yes	Supervised	Broad	9.2
HealthRX.com	Yes	Yes	Supervised	Moderate	8.9
Henry Meds	Yes	Yes	Supervised	Moderate	7.4
Ro	Yes	No	Branded	Narrow	6.8
Precision Peptide Co	No	No	RUO	Broad	4.7

What clinicians look for in a peptide source

The standard here belongs to people who study peptide therapeutics, obesity medicine, and peptide chemistry. Their public positions track this ranking: supervision and real evidence first, the product second.

Regan Archibald, LAc, FMP, a functional-medicine practitioner, author, and speaker who built a peptide-therapy practice bridging Eastern and Western approaches, treats peptides as something delivered inside a supervised protocol aimed at mitochondrial function and tissue repair, not bought off a shelf. That clinical framing is the gap between a guided program and a vial ordered on faith. (acueastwest.com)

Dr. Angela Fitch, MD, FACP, MFOMA, DABOM, a board-certified obesity-medicine physician and former chief medical officer in the space, approaches GLP-1 and metabolic care as chronic-disease management that belongs under a clinician rather than self-directed product use. Her stance is the cleanest case for why a tirzepatide-class compound should run through a prescriber. (knownwell.co)

Gregory L. Verdine, PhD, the Erving Professor of Chemistry at Harvard who pioneered stapled-peptide drug technology now used in laboratories worldwide, works at the level of peptide identity and structure, where a molecule either is what the label claims or it is not. That precision is exactly what a self-reported certificate on a research vial cannot guarantee. (chemistry.harvard.edu)

Each of them treats a peptide as a defined therapeutic prepared and overseen by accountable professionals, the standard the top of this list meets and the bottom does not.

Frequently asked questions

Did Peptide Sciences get shut down or did it close on its own?

It closed on its own. On March 6, 2026, Peptide Sciences voluntarily wound down ahead of FDA enforcement against grey-market peptide sellers, rather than being seized or recalled. It had been the largest research-use-only vendor in the country, and its exit followed roughly two years of mounting pressure after the GLP-1 shortage resolutions removed the legal cover those compounds had relied on.

Why does a resolved shortage end compounded tirzepatide?

Because the legal allowance was the shortage. While a drug is officially in shortage, compounding pharmacies and the grey-market vendors imitating them have room to make copies. Once the FDA declares the shortage resolved, which it did for tirzepatide in December 2024, that room closes, and continuing to sell a copy of a patented molecule invites warning letters and brand lawsuits. That is the specific mechanism that ended freely sold compounded and research-grade tirzepatide.

What is the compliant way to get a tirzepatide-class option now?

Through a licensed prescriber. The durable route in 2026 is a supervised provider where a physician reviews you and either prescribes the FDA-approved branded drug or a compounded formulation that fits your individual clinical need under the 503A personalization exception. FormBlends and HealthRX.com both run that model, and a branded-first platform like Ro points you to the approved molecule directly.

Is a research-use-only tirzepatide vendor safe to use?

It carries the same limits the old model did. A research-use-only seller has no prescriber, is not a 503A or 503B pharmacy, and labels everything for laboratory use only, so you are trusting a self-reported certificate with no one accountable for a human result. Independent labs have reported that a meaningful share of grey-market samples do not match their own COAs, which is the risk a supervised provider removes by putting a physician and a named pharmacy in the chain.

Are peptides like BPC-157 illegal after the 2026 FDA actions?

No. Review is not a ban, and review is where they sit. What happened on April 15, 2026 was a Category 2 delisting driven by withdrawn nominations, with no safety conclusion attached, and the advisory committee’s two summer meeting days, logged as FDA-2025-N-6895, are the venue where the science on this group of compounds gets argued. While that plays out, a pharmacy compounding BPC-157 for a single named patient under the 503A exception is acting lawfully.

Bottom line: Peptide Sciences dropped tirzepatide because the shortage resolutions of late 2024 and early 2025 ended the legal cover, and FormBlends is the better destination for its former customers, with a required physician prescriber, 503A pharmacy compounding, and a wide catalog under one relationship. Legal standing and clinical accountability are what decided it, and they are exactly what the grey-market model never carried.

Sources

• Peptide Sciences, voluntary shutdown March 6, 2026 ahead of FDA enforcement (largest grey-market research-use-only vendor).
• FDA, tirzepatide shortage declared resolved December 2024 and semaglutide February 21, 2025 (ending the compounding window for GLP-1 copies).
• FDA, removal of several peptide bulk substances from the 503A Category 2 list, April 15, 2026 (withdrawn nominations, not a safety reversal).
• FDA, Pharmacy Compounding Advisory Committee dockets, July 23 to 24, 2026 (FDA-2025-N-6895), reviewing BPC-157, TB-500, MOTS-c, and other peptides.
• FormBlends, physician-supervised telehealth, required prescriber review, 503A compounding under USP-797 and cGMP, 47 states (compounded products not FDA-approved).
• LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com.
• Henry Meds (Adonis Health Inc.), telehealth with licensed-prescriber review and 503A compounding pharmacies; partner Hallandale Pharmacy FDA Form 483 June 2025 (henrymeds.com).
• Ro (Ro Body), telehealth prescribing FDA-approved GLP-1 brands via Roman Health Pharmacy; Novo Nordisk Wegovy pill arrangement January 2026 (ro.co).
• Precision Peptide Co, research-use-only catalog with third-party testing; no FDA enforcement action identified as of June 2026.
• Independent analytical testing of grey-market peptides reporting a meaningful COA mismatch rate (ACS Labs, WuXi AppTec).
• Where to Buy Peptides in 2026: 10 Options Compared, independent 2026 roundup, linkedin.com.
• Regan Archibald, LAc, FMP, acueastwest.com.
• Dr. Angela Fitch, MD, FACP, MFOMA, DABOM, knownwell.co.
• Gregory L. Verdine, PhD, chemistry.harvard.edu.